SUZHOU, China, December 30, 2021 — Dr. Jinzhong Zhang, Co-founder, Chairman and CEO of Eluminex Biosciences (Suzhou) Limited (Eluminex) was invited as a guest speaker at the DeviceChina 2021, held by BioBAY, Suzhou Industrial Park, on October 24, 2021, where Dr. Zhang gave a presentation on the recent progress on biologics drug development in retinal diseases. On November 17, 2021, Dr. Zhang was invited as a panelist to the China Healthcare Summit, which was jointly organized by BioCentury and BayHelix. At this Summit, Dr. Zhang shared the Eluminex vision as an innovation-driven ophthalmic biotech company and his views on opportunities and challenges of China biomedical industry.

Dr. Jinzhong Zhang received his PhD in Molecular Biology through a joint program between Peking University and Kyoto University and served as an Assistant Professor of Ophthalmology at Case Western Reserve University. He served as Principal Investigators on 5 research projects of diabetic retinopathy awarded by the National Eye Institute of the National Institutes of Health (NIH) and the American Diabetes Association (ADA). With 25 years in ophthalmic research and drug development in the United States and Japan, Dr. Zhang has held senior leadership roles in both private (Graybug Vision; Nasdaq: GRAY) and large global ophthalmology companies (Santen Pharmaceutical and Bausch + Lomb) and led in the research and development of several marketed products.